Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2024-11-06 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
We are enclosing herewith the certificate dated November 6, 2024 issued by the RTA of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, ...
Regulatory Filings Classification · 95% confidence The document is a certificate issued pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance related to dematerialization of securities for the period 01.10.2024 to 31.10.2024. It is addressed to stock exchanges and signed by the company secretary and the registrar and transfer agent. The document is short (3229 characters) and primarily serves as a compliance certificate rather than a full financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is not an announcement of a report publication but a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance certificates and miscellaneous regulatory documents.
2024-11-06 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about an upcoming Board of Directors meeting scheduled for November 13, 2024. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2024. The document also mentions the closure of the trading window for designated persons due to insider trading regulations. The document is short (1505 characters) and serves as a notification of a future event rather than containing any financial data or results itself. It does not contain actual financial statements or detailed analysis, nor is it a report or transcript. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-10-25 English
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 ,inter alia, to consider and approve the Unaudited Financial ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about an upcoming Board of Directors meeting scheduled for November 13, 2024. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2024. The letter also mentions the closure of the trading window for designated persons due to insider trading regulations. The document is short (1505 characters) and serves as a notification of a future event rather than containing any financial data or results itself. It does not contain actual financial statements or detailed analysis, nor is it a report or transcript. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2024-10-25 English
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of ....
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the appointment of a senior management personnel, Ms. Amita Bhave, as Director – Regulatory Affairs. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in senior management. The content includes details about the appointment, effective date, and a brief profile of the appointee. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of a management change rather than a full management report or other filing type. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 3140 characters, which is consistent with a brief announcement rather than a full report.
2024-10-25 English
General Updates
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the appointment of a senior management personnel, Ms. Amita Bhave, as Director – Regulatory Affairs. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in senior management. The content includes details about the appointment, effective date, and a brief profile of the appointee. There are no financial statements, earnings data, or report attachments. The document is clearly an announcement of a management change rather than a full report or financial filing.
2024-10-25 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) regarding the loss of share certificates by a shareholder. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 39(3), which pertains to share certificate loss and related disclosures. The content is an announcement of an event (loss of share certificates) and the company's intention to issue a Letter of Confirmation after formalities are completed. The document is short (1685 characters) and does not contain financial data, management discussion, or detailed report content. It is not a financial report, earnings release, or management report. It is a regulatory announcement related to shareholding records and compliance. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-10-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.